Enlivex Therapeutics Ltd. - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Enlivex Therapeutics Ltd. (Israel) covers the month of October 2023. The report details the status of the Company's 2023 Annual General Meeting of Shareholders held on October 26, 2023.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural notice regarding a shareholder meeting and does not contain financial statements.
Material Changes
No material financial changes versus prior periods are reported in this document. The primary event is the adjournment of the Annual General Meeting due to a lack of quorum.
Outlook, Risks, and Unusual Items
The Annual Meeting was adjourned for one week and will be reconvened on Thursday, November 2, 2023, at 7:00 p.m. Israel time at the Company's offices in Ness Ziona, Israel. Consequently, voting deadlines have been extended:
- Mail-in Proxy Deadline: Extended to October 30, 2023, by 7:00 p.m. Israel time.
- Telephone/Internet Voting Deadline: Extended to October 29, 2023, by 11:59 p.m.
Key Facts for Investor Verification
- The 2023 Annual General Meeting was adjourned on October 26, 2023, due to a lack of quorum.
- The reconvened meeting is scheduled for November 2, 2023.
- Shareholders must adhere to the extended voting deadlines to participate in the reconvened meeting.
- This filing contains no financial performance data.